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Purpose: To report a case of central retinal artery occlusion (CRAO) in a patient with 
metabolic syndrome X.
Case Report: A 64 year-old-man presented with abrupt, painless, and severe loss 
of vision in his left eye. Indirect ophthalmoscopy disclosed signs compatible with 
CRAO and laboratory investigations revealed erythrocyte sedimentation rate of   
74 mm/h, C-reactive protein (CRP) level of 21 mg/l, hyperglycemia, hyperuricemia, 
hypertriglyceridemia and hypercholesterolemia. Fluorescein angiography and 
immunological studies excluded other systemic disorders. The patient met the full 
criteria of the National Cholesterol Education Program for metabolic syndrome X.
Conclusion: In addition to different vascular complications such as stroke, and 
cardiovascular disease, metabolic syndrome X may be associated with retinal vascular 
occlusions. 
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INTRODuCTION
Central retinal artery occlusion (CRAO) is one 
of the most urgent and dramatic conditions 
in ophthalmology. It occurs when blockage 
in the central retinal artery develops within 
the optic nerve substance, therefore the site of 
obstruction is not visible on ophthalmoscopy. 
The hallmark of retinal artery obstruction is 
abrupt and painless loss of vision. Amaurosis 
fugax precedes visual loss in about 10% of 
patients.1 Rarely, in cases associated with arterial 
spasm, a relapsing and remitting course of 
visual loss may occur prior to CRAO.1,2
Within  minutes  to  hours  after  the 
obstruction, the fundus may appear relatively 
normal. A cherry-red spot in the macula is 
typical for this condition and is due to thinness 
of the retinal nerve fiber layer in the fovea 
allowing transmission of the normally perfused 
choroid underneath. The retina becomes opaque 
elsewhere and blocks the brownish-red color 
of the choroid.
Conditions associated with CRAO include 
atherosclerotic cardiovascular disease (CVD); 
coagulopathic conditions; oncologic, radiologic 
and medical procedures; systemic vasculitis 
and infections; local trauma; and local ocular 
conditions such as prepapillary arterial loops, 
optic nerve drusen, necrotizing herpetic retinitis, 
orbital mucuromycosis and toxoplasmosis.3
The metabolic syndrome X (MetS) is 
characterized by abdominal obesity, glucose 
intolerance, dyslipidemia, high blood pressure 
and hyperuricemia.4 According to the National 
Cholesterol Education Program (NCEP) criteria, Metabolic Syndrome and CRAO; Cekic et al
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MetS is diagnosed when three or more of 
the following criteria are present: abdominal 
type obesity, triglyceride level more than 
1.7 mmol/l, high-density lipoprotein (HDL) 
cholesterol <1.0 mmol/l, blood pressure higher 
than 130/85 mmHg, and fasting glucose>   
6.1 mmol/l.4,5 Many studies have suggested that 
arteriosclerosis and insulin resistance share a 
common inflammatory basis by demonstrating 
raised C-reactive protein (CRP) levels and a 
direct harmful effect on vascular walls.6-9
CASE REPORT
A 64 year-old-man presented with abrupt, 
painless, and severe visual loss to counting 
fingers at 1 m in his left eye; best-corrected 
visual acuity was 20/20 in his right eye. He had 
noted temporary visual loss of a few seconds’ 
duration in the same eye a few days before 
total visual loss. Intraocular pressure was 19 
mmHg and the anterior segment was normal 
in both eyes, but afferent pupillary defect 
was present in the left eye. The right fundus 
was normal (Fig. 1), however in the left eye, 
ophthalmoscopy and fluorescein angiography 
showed narrowing of retinal arteries, box-
carring and fragmentation of blood flow in 
the retinal arterioles, the retina was opaque 
and a cherry-red spot was present (Fig. 2). 
Angiography revealed a prolonged arm-retina 
time, prolonged filling of retinal arteries, and a 
long arteriovenous time, as well as late staining 
of the optic nerve head with peripapillary 
splinter hemorrhages and disseminated retinal 
hemorrhages in all quadrants (Fig. 3). 
The following laboratory tests were raised 
above normal limits: fibrinogen 6.1 g/l, CRP 
34 mg/l, serum glucose 6.9 mmol/l, HbA1C 
7.2, uric acid 451.8 mol/l, total cholesterol 
7.5 mmol/l, HDL 0.9 mmol/l, low-density 
lipoprotein (LDL) 5.0 mmol/l, triglycerides   
2.1 mmol/l, and erythrocyte sedimentation rate 
42 mm/h. Complete blood count (red blood cells, 
Figure 1. Fundus photograph of the right eye. Figure 2. Fundus photograph of the left eye: note the 
splinter hemorrhages and cherry-red spot.
Figure 3. Fluorescein angiography in the left eye of the patient.Metabolic Syndrome and CRAO; Cekic et al
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white blood cells and platelets) was normal. 
Prothrombine time was 85% and the activated 
partial thromboplastin time was 26 seconds. 
Rheumatic factor, antinuclear antibodies, anti-
neutrophil cytoplasmic antibodies, immune 
complexes, and antiphospholipid antibodies 
were negative.
Clinical examination revealed abdominal 
obesity and systemic hypertension (160/110 
mmHg). A color Doppler scan of the carotid 
arteries showed bilateral stenosis, 45% on the 
right side and 64% on the left. Holter monitoring 
revealed normal cardiac rhythm.
DISCuSSION
This case report may reflect the need for 
changing the approach to the patient with CRAO 
and to point out that complex metabolic changes 
may be involved in its pathogenesis. Abrupt 
unilateral visual loss is a symptom in different 
ophthalmic disorders and is most frequently 
seen in retrobulbar optic neuritis, anterior 
ischemic optic neuropathy, severe commotio 
retinae, necrotizing herpetic retinitis, central 
or branch retinal vein occlusion (CRVO or 
BRVO) and CRAO.2,3 Typical findings in fundus 
examination and fluorescein angiography help 
to exclude diagnoses other than CRAO. 
The disseminated retinal hemorrhages 
present in all retinal quadrants in our patient 
and peripapillary splinter hemorrhages may 
point toward vasculitis as the etiology for 
the vaso-occlusive phenomenon. However, 
standard and immunological laboratory 
investigations excluded systemic vasculitis, 
hypercoagulability states and anti-phospholipid 
antibody syndrome, but suggested a metabolic 
disorder due to the presence of abdominal 
obesity, diabetes mellitus, dyslipidemia, high 
blood pressure and hyperuricemia. The patient 
reported herein demonstrated all five NCEP 
criteria for MetS.
The raised proinflammatory marker levels 
(CRP, fibrinogen) in the MetS are also classic 
risk factors for CVD and stroke. In the last 
decade, low grade inflammation has been 
identified as a pivotal pathogenic factor for 
development of atherosclerosis and has been 
shown to predict myocardial infarction and 
stroke in patients with pre-existing CVD.7-11   
CRP has been investigated extensively in 
the context of atherosclerosis and vascular 
complications. Increased CRP is associated with 
an increased risk of CVD. CRP may also be an 
important marker for complications of MetS 
such as CRAO.12-14 It has been suggested that 
inflammation might be an important trigger 
for acute coronary events related to plaque 
rupture rather than a promoter of chronic 
atherosclerosis. It has also been proposed that 
CRP might play an atherogenic role through 
interaction with low density lipoproteins. CRP 
level is an important marker in the follow-up 
of all conditions related to atherosclerosis.9-15
In summary, the case presented herein 
demonstrates that CRAO may be associated 
with MetS and result in profound visual loss. 
The vascular occlusion is multifactorial and 
often requires a multidisciplinary approach. 
It is closely associated with CVD and stroke. 
Inflammation seems to be an important trigger 
for CVD, stroke and MetS. 
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